The Clinical Evaluation of Implantable Pump System For Safety And Delivery Accuracy In Patients Requiring Intrathecal Administration Of Morphine Sulfate For Chronic Pain

Chronic Pain Clinical Trial

Official title:

THE CLINICAL EVALUATION OF IMPLANTABLE PUMP SYSTEM FOR SAFETY AND DELIVERY ACCURACY IN PATIENTS REQUIRING INTRATHECAL ADMINISTRATION OF MORPHINE SULFATE FOR CHRONIC PAIN

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01185470
• Other study ID #: P100
• Status: Completed
• Phase: Phase 2/Phase 3
• First received: August 18, 2010
• Last updated: April 20, 2017
• Start date: February 2011
• Est. completion date: July 2016

Study information

• Verified date: April 2017
• Source: Medallion Therapeutics, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

• The objectives of this study are to confirm the medication delivery accuracy of the Infusion System, LLC Implantable Drug Delivery System (IDDS) with Patient Controlled Analgesia for intrathecal delivery of morphine sulfate for pain control, and to determine the safety profile of the system with PCA for intrathecal delivery of morphine sulfate for pain control.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 75
• Est. completion date: July 2016
• Est. primary completion date: January 2015
• Accepts healthy volunteers: No
• Gender: All
• Age group: 21 Years and older

Eligibility

Inclusion Criteria:

1. Subject must be at least 21 years of age.

2. Subject must have experienced chronic pain for at least 6 months.

3. Subject must not presently be on intrathecal therapy but must be considered a candidate for intrathecal analgesia by his pain specialist; or, a subject already on intrathecal therapy must be in need of a replacement intrathecal pump and catheter.

4. Subject must be capable of giving informed consent.

5. Subjects who agree to sign a Pain Treatment Agreement (Narcotic Contract) limiting narcotic prescriptions to the study physician.

6. Subjects who agree to periodic drug testing.

7. Subject must be capable and willing to follow all study-related procedures, including returning for monthly refills.

8. Subject must be cognitively intact and, in the opinion of the Investigator, capable of using the Patient Remote.

9. Subject who is not already successfully treated with intrathecal analgesic therapy must be responsive to a trial of intrathecal or epidural morphine.

10. Female subjects of child-bearing potential must agree to use a medically acceptable and effective double-barrier method of birth control.

11. Documented failure to respond to less invasive methods of pain control (such as physical or behavioral modifications).

12. Ineffective pain control with single or multiple systemic analgesic treatments (oral, rectal, IV or transdermal) or had intolerable side effects.

13. Cancer pain requiring strong opioids or non-malignant pain with average Visual Analog Scale (VAS) score of = 4/10.

14. Subjects who can receive an MRI.

15. Subjects must be able to hear and respond to audible alarms or agree to have a support person available who is able to hear and respond to audible alarms.

Exclusion Criteria:

1. Subject is a female who is pregnant or is planning a pregnancy.

2. Subject is a nursing mother.

3. Subject has at the site chosen for implantation a skin condition that would prevent the implantation procedure.

4. Subject has participated in an investigational drug or device trial within 4 weeks prior to enrollment.

5. Subject has any known or suspected allergy to morphine or to the materials of the infusion pump or intrathecal catheter.

6. Subject shows signs of active, systemic infection.

7. Subject has a known central nervous system contraindication to intrathecal therapy, including but not limited to severe spinal canal stenosis or spinal cord compression.

8. Subject has a body size that is insufficient to accept the bulk and weight of the pump.

9. Subject is allergic to morphine sulfate, or for whom morphine sulfate is contraindicated.

10. Subject has a condition requiring diathermy procedures.

11. Subject has a life expectancy of less than 9 months.

12. Subject cannot independently comprehend and participate in the required assessments, including responding to the QOL, BPI, ODI and PGIC measurement tools.

13. Subject is not considered to be medically or psychologically appropriate for pump implantation.

14. Subject has a urine drug screen result which indicates the use of prescription drugs or controlled substances not on the order of a physician.

15. Subjects with an ASA Physical Status >IV.

16. Subjects with a history of spinal instability, or grade II spondylolisthesis or greater.

17. Previously implanted subjects with spinal MRI findings of inflammatory mass prior to the implantation procedures.

18. Subjects who are unable or unwilling to return to all of the required follow-up visits.

19. Subjects who are unwilling to sign the informed consent.

20. Subjects who are exposed to high-current industrial equipment (i.e. electricians or electrical engineers) or regularly exposed to MRI equipment (i.e. MRI technicians, MRI engineers and MRI clinicians).

21. Subjects with active implanted devices such as pacemakers, defibrillators, cochlear implants and neurostimulators or other medical device use that can interfere with the function of the implanted intrathecal pump.

Related Conditions & MeSH terms

• Cancers
• Chronic Pain

Intervention

Device:
• Implantation of Morphine Sulfate delivering programmable pump
Patients with chronic pain responsive to intrathecal opioid analgesia as demonstrated in a morphine trial or patients with a previous successful intrathecal opioid therapy with an implantable pump will undergo implantation of pump for intrathecal delivery of Morphine Sulfate.

Locations

Country	Name	City	State
United States	Millenium Pain Center	Bloomington	Illinois
United States	Coastal Pain Research	Carlsbad	California
United States	Pain Research of Oregon	Eugene	Oregon
United States	Global Scientific Innovations, LLC	Evansville	Indiana
United States	University of California San Diego	La Jolla	California
United States	Neurovations	Napa	California
United States	Center for Pain Management	Saint Louis	Missouri
United States	Center for Pain & Supportive Care	Scottsdale	Arizona
United States	The Center for Clinical Research	Winston-Salem	North Carolina

Sponsors (1)

Lead Sponsor	Collaborator
Medallion Therapeutics, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	• Mean medication delivery accuracy.	Medication delivery accuracy will be evaluated at each of six (6) refills.	6 months
Secondary	• Tabulation of Adverse Events		12 months
Secondary	Concomitant Medications, Physical and Neurological Exam, Inflammatory Masses, Vital Signs, Incidence of Inflammatory Masses, Summary of COWS	Tabulation of Concomitant Medications, Tabulation of Physical and Neurological, Exam, Summary of Vital Signs, Incidence of Inflammatory Masses, Summary of COWS	6 months